Subcutaneous (SC) abatacept

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Rheumatoid ArthritisRheumatoid Arthritis (RA)

Phase 2

Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients

CompletedNCT01001832

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2009-12-31End: 2012-10-31Updated: 2014-02-06

Phase 3

Methotrexate-Inadequate Response Study

CompletedNCT00559585

Bristol-Myers SquibbRheumatoid Arthritis (RA)

Start: 2008-01-31End: 2014-09-30Updated: 2015-11-09

Related Papers

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

2017-08-1824 citations

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

BMC Musculoskeletal Disorders2016-05-2672 citations

Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.

2015-09-0111 citations

Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.

2014-04-0715 citations

Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial

The Journal of Rheumatology2014-03-0133 citations